I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Recurso digital |
| Reo: | Ingarihi |
| I whakaputaina: |
Zenodo
2026
|
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.5281/zenodo.19365865 |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Rārangi ihirangi:
- This extensive technical review provides a multidimensional analysis of the global landscape of Neglected Tropical Diseases (NTDs) and antimicrobial resistance, targeting researchers, scientists, and drug development professionals. Driven by the World Health Organization's 2021-2030 road map, global efforts have successfully reduced the population requiring NTD interventions by 32 percent since 2010, bringing the total down to 1.495 billion in 2023. The burden of disease, measured in disability-adjusted life years (DALYs), has correspondingly fallen to 14.1 million. Furthermore, 54 countries successfully eliminated at least one NTD by the end of 2024. Despite these milestones, the NTD research and control ecosystem faces severe structural and environmental threats. A critical 41 percent decline in official development assistance between 2018 and 2023 has exposed the fragility of NTD financing, necessitating innovative funding mechanisms and domestic resource mobilization. Concurrently, climate change is altering vector transmission dynamics, and the rise of drug-resistant pathogens, including extensively drug-resistant bacteria and resistant parasitic strains, threatens the efficacy of existing chemotherapies. To overcome the historical market failure in NTD research and development, the article emphasizes the success of Product Development Partnerships and not-for-profit models that de-risk investment and facilitate the delivery of billions of donated treatments. The text also details modern drug discovery workflows that integrate phenotypic screening, artificial intelligence, and multi-target drug design to accelerate the identification of novel therapeutics. Additionally, the development and WHO prequalification of point-of-care diagnostics and new vaccines, such as the recently approved dengue vaccine, are highlighted as essential components of the elimination toolkit. Finally, the whitepaper advocates for a paradigm shift from vertical, disease-specific programs to integrated health system approaches. By mainstreaming NTD services into primary healthcare, enhancing national surveillance data systems, and addressing fundamental cross-cutting gaps like Water, Sanitation, and Hygiene and gender equity, the global health community can build resilient frameworks capable of sustaining progress and ultimately eliminating these diseases of poverty. Source: https://www.parasitestudy.com/posts/the-global-burden-of-neglected-tropical-diseases-current-progress-scientific-challenges-and-the-future-of-drug-development